Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice

Atherosclerosis

Volumn 224, Issue 2, 2012, Pages 326-331

  Nayyar, Gaurav ^a   Garber, David W ^a   Palgunachari, Mayakonda N ^a   Monroe, Candyce E ^a   Keenum, Tamara D ^a   Handattu, Shaila P ^a   Mishra, Vinod K ^a   Anantharamaiah, G M ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Atherosclerosis; Cholesterol; Inflammation; Oxidation; Peptides

Indexed keywords

ACETYL LEUCYLARGINYLLYSYLLEUCYLARGINYLLYSYLARGINYLLEUCYLLEUCYLASPARTYLTRYPTOPHYLLEUCYLLYSYLALANYLPHENYLALANYLTYROSYLASPARTYLLYSYLVALYLALANYLGLUTAMYLLYSYLLEUCYLLYSYLGLUTAMYLALANYLPHENYLALANINE AMINE; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE 1; ASPARTYLTRYPTOPHYLPHENYLALANYLLYSYLALANYLPHENYLALANYLTYROSYLASPARTYLLYSYLVALYLALANYLGLUTAMYLLYSYLPHENYLALANYLLYSYLGLUTAMYLALANYLPHENYLALANINE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LIPID HYDROPEROXIDE; SERUM AMYLOID A; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROORBITAL ADMINISTRATION ROUTE;

AGE FACTORS; AGING; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICHOLESTEREMIC AGENTS; ANTIOXIDANTS; AORTIC DISEASES; APOLIPOPROTEIN A-I; APOLIPOPROTEINS E; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; CHOLESTEROL; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; LIPID PEROXIDES; LIPOPROTEINS; MICE; MICE, KNOCKOUT; PEPTIDE FRAGMENTS; SERUM AMYLOID A PROTEIN; SEX FACTORS; TIME FACTORS;

EID: 84866538361     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.05.040     Document Type: Article

References (37)

1. Chait A., Weight T.N. Interaction of low density lipoproteins with extracellular matrix. Curr Opin Lipidol 2000, 11:457-463.
2. Duffy R., Rader D.J. Drugs in development: targeting high-density lipoprotein metabolism and reverse cholesterol transport. Curr Opin Cardiol 2005, 20:301-306.
3. Brousseau M.E. Emerging role of high density lipoprotein in the prevention of cardiovascular disease. Drug Discov Today 2005, 10:1095-1099.
4. Benoit P.P., Emmanuel F.P., Caillaud J.M., et al. Somatic gene transfer of human apoA-I inhibits atherosclerosis progression in mouse models. Circulation 1999, 99:105-110.
5. Moore R.E., Kawashiri M.A., Kitajima K., et al. Apolipoprotein A-I deficiency results in markedly increased atherosclerosis in mice lacking the LDL receptor. Arterioscler Thromb Vasc Biol 2003, 23:1914-1920.
6. Boisvert W.A., Spangenberg J., Curtiss L.K. Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by bone marrow transplantation. J Clin Invest 1995, 96:1118-1124.
7. Linton M.F., Atkinson J.B., Fazio S. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science 1995, 267:1034-1037.
8. Harris J.D., Schepelmann S., Athanasopoulos T., et al. Inhibition of atherosclerosis in apolipoprotein-E-deficient mice following muscle transduction with adeno-associated virus vectors encoding human apolipoprotein-E. Gene Ther 2002, 9:21-29.
9. Raffai R.L., Loeb S.M., Weisgraber K.H. Apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels. Arterioscler Thromb Vasc Biol 2005, 25:436-441.
10. Anantharamaiah G.M. Synthetic peptide analogs of apolipoproteins. Methods Enzymol 1986, 128:627-647.
11. Sparrow J.T., Gotto A.M., Morrisett J.D. Chemical synthesis and biochemical properties of peptide fragments of apolipoprotein alanine. Proc Natl Acad Sci USA 1973, 70:2124-2128.
12. Fukushima D., Yokoyama S., Kézdy F.J., Kaiser E.T. Binding of amphiphilic peptides to phospholipid/cholesterol unilamellar vesicles: a model for protein-cholesterol interaction. Proc Natl Acad Sci USA 1981, 78:2732-2736.
13. Anantharamaiah G.M., Mishra V.K., Garber D.W., et al. Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides. J Lipid Res 2007, 48:1915-1923.
14. Sharifov O.F., Nayyar G., Garber D.W., et al. Apolipoprotein E mimetics and cholesterol lowering properties. Am J Cardiol Drugs 2011, 11:371-381.
15. Anantharamaiah G.M., Jones J.L., Brouillette C.G., et al. Studies of synthetic peptide analogs of the amphipathic helix. J Biol Chem 1985, 260:10248-10255.
16. Venkatachalapathi Y.V., Phillips M.C., Epand R.M., et al. Effect of end group blockage on the properties of class A amphipathic helix. Proteins 1993, 15:349-359.
17. Garber D.W., Datta G., Chaddha M., et al. A new synthetic class A amphipathic helical peptide analog protects mice from diet-induced atherosclerosis. J Lipid Res 2001, 42:545-552.
18. Navab M., Anantharamaiah G.M., Hama S., et al. Oral administration of an apoA-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 2002, 105:290-302.
19. Kruger A.L., Peterson S., Turkseven S., et al. D-4F induces heme oxygenase-1and extracellular superoxides dismutase, decrease endothelial cell sloughing and improves vascular reactivity in rat model of diabetes. Circulation 2005, 111:3126-3134.
20. Ou Z., Ou J., Akerman A.W., Oldham K.T., Prichard K.A. L-4F, an apoA-I mimetic restores nitric oxide and superoxide anion balance in low-density lipoprotein-treated endothelial cells. Circulation 2003, 107:1520-1524.
21. Ou J., Wang J., Xu J., et al. Effect of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor null and LDL receptor null/apoA-I double knockout mice on Western diet. Circ Res 2005, 97:1190-1197.
22. Nayyar G., Mishra V.K., Handattu S.P., et al. Sidedness of interfacial arginine residues and anti-atherogenicity of apolipoprotein A-I mimetic peptides. J Lipid Res 2012, 53:849-858.
23. Mahley R.W., Weisgraber K.H., Husein M.M., et al. Intravenous infusion of apolipoprotein E accelerates clearance of plasma lipoproteins in rabbits. J Clin Invest 1989, 83:2125-2130.
24. Bradley W.A., Gilliam E.B., Gotto A.M., Gianturco S.H. Apolipoprotein E degradation in human very low density lipoproteins by protease(s): chemical and biological consequences. Biochem Biophys Res Commun 1982, 109:1360-1367.
25. Datta G., Chaddha M., Garber D.W., et al. The receptor binding domain of apolipoprotein E linked to a model class A amphipathic helical peptide enhances internalization and degradation of LDL by fibroblasts. Biochemistry 2000, 39:213-220.
26. Datta G., Garber D.W., Chung B.H., et al. Cationic domain 141-150 of apoE covalently linked to a class A amphipathic helix enhances atherogenic lipoprotein metabolism in vitro and in vivo. J Lipid Res 2001, 42:959-966.
27. Garber D.W., Handattu S., Aslan I., Datta G., Chaddha M., Anantharamaiah G.M. Effect of an arginine rich amphipathic helical peptide on plasma cholesterol in dyslipidemic mice. Atherosclerosis 2003, 168:229-237.
28. Gupta H., White C.R., Handattu S., et al. Apolipoprotein E mimetic peptide dramatically lowers plasma cholesterol and restores endothelial function in Watanabe Heritable hyperlipidemic rabbits. Circulation 2005, 111:3112-3118.
29. 2. Atherosclerosis 2010, 208:131-141.
30. Nayyar G., Handattu S., Monroe C.E., et al. Two adjacent domains (141-150 and 151-160) of apoE covalently linked to a class A amphipathic helical peptide exhibit opposite atherogenic effects. Atherosclerosis 2010, 213:449-457.
31. Palgunachari M.N., Mishra V.K., Lund-Katz S., et al. Only the two end helixes of eight tandem amphipathic helical domains of human apo A-I have significant lipid affinity: implications for HDL assembly. Arterioscler Thromb Vasc Biol 1996, 16:328-338.
32. Palinski W., Ord V.A., Plump A.S., Breslow J.L., Steinberg D., Witztum J.L. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb Vasc Biol 1994, 14:605-616.
33. Gan K.N., Smolen A., Eckerson H.W., La Du B.N. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Disp 1991, 19:100-106.
34. Draganov D.I., Stetson P.L., Watson C.E., Billecke S.S., La Du B.N. Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem 2000, 275:33435-33442.
35. Navab M., Hama S.Y., Hough G.P., Subbanagounder G., Reddy S.T., Fogelman A.M. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res 2001, 42:1308-1317.
36. Vaziri N.D., Moradi H., Pahl M.V., Fogelman A.M., Navab M. In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-I mimetic peptide. Kidney Internat 2009, 76:437-444.
37. Navab M., Shechter I., Anantharamaiah G.M., Reddy S.T., Van Lenten B.J., Fogleman A.M. Structure and function of HDL mimetics. Arterioscler Thromb Vasc Biol 2010, 30:164-168.